Monoclonal antibodies
Monoclonal antibodies are laboratory-made proteins.
It mimic the behavior of antibodies produced by the immune system to protect against diseases and foreign substances.
An antibody attaches itself to an antigen.
Immune system eliminate the disease-causing molecule from the body.
Monoclonal antibodies are specifically designed to target certain antigens.
What is m102.4?
It’s a monoclonal antibody that neutralises Hendra and Nipah viruses in and outside of living organisms.
The antibody passes phase one of clinical trails.
The m102.4 already tested in less number of people to identify its correct dosage and side effects.
Now this drug is available under “compassionate use”.
Compassionate use means, a treatment option that allows the use of an unauthorized medicine under strict conditions among people where no other alternative treatment possible.
How do monoclonal antibodies work?
Monoclonal antibodies are specifically engineered and generated to target a disease.
They are meant to attach with a specific disease-causing antigen, most likely to be a protein.
The binding prevented the protein from exercising its regular functions, including its ability to infect other cells.
Hybridoma – a fusion cell made up of B cells (white blood cells that produce antibodies) and myeloma cells (abnormal plasma cells.
These hybrid cells produce single cell antibody know as monoclonal antibody.
Today, these antibodies are made using recombinant DNA technology.
Glycoproteins are one of the major components of viruses that cause diseases in humans.
The m102.4 monoclonal antibody binds itself to the immunodominant receptor-binding glycoprotein of the Nipah virus, potentially neutralising it.
COMMENTS